BeiGene's Brukinsa (zanubrutinib) Receives the NMPA's Approval for Relapsed or Refractory Waldenström's Macroglobulinemia
Shots:
- The conditional approval is based on results from a P-II trial in China evaluating the safety & efficacy of Brukinsa in patients with WM who have received at least one prior therapy
- Results: @median follow-up time of 14.9mos.- MRR (72.1%) as assessed by IRC & AEs profile was generally consistent with previous findings
- Brukinsa is a BTK inhibitor & marks the third approval for the treatment of B-cell malignancies in China- currently being evaluated in multiple clinical studies globally as a monothx. or in combination with other therapies targeting B cell malignancies
| Ref: Business Wire | Image: BioSpace
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
